Research summary

LL-37 is the only cathelicidin antimicrobial peptide produced by humans, a 37-amino-acid fragment of the hCAP-18 precursor protein, studied for direct antimicrobial membrane disruption, anti-biofilm activity, and recruitment of immune cells via formyl peptide receptor signaling.

A 2021 phase IIb randomized controlled trial in 148 patients found complete wound closure in 28.1% of large wounds treated with LL-37, versus 8.1% with placebo. In mouse studies, delivery of LL-37 to wounds in diabetic (ob/ob) mice significantly improved re-epithelialization and granulation tissue formation versus untreated wounds.

Sources: Phase IIb RCT, 2021; PMC3699762; Journal of Investigative Dermatology (component mouse studies). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.

Decoding the Benefits

More than tripled the complete-healing rate for large wounds compared with placebo in a 148-patient trial.
The only antimicrobial peptide the human body produces natively, giving it a dual role in infection defense and healing.